This brand name is authorized in Germany, Finland, Poland
The drug CLIOVELLE contains a combination of these active pharmaceutical ingredients (APIs):
1
Estradiol
UNII OKG364O896 - ESTRADIOL VALERATE
|
Estradiol, is chemically and biologically identical to endogenous human estradiol. It substitutes for the loss of oestrogen production in menopausal women, and alleviates menopausal symptoms. Oestrogens prevent bone loss following menopause or ovariectomy. |
2
Norethisterone
UNII 9S44LIC7OJ - NORETHINDRONE ACETATE
|
Norethisterone has progestational actions similar to those of progesterone, but is a more potent inhibitor of ovulation and has weak oestrogenic and androgenic properties. It is used to treat a number of disorders of the menstrual cycle. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
G03FA01 | Norethisterone and estrogen | G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03F Progestogens and estrogens in combination → G03FA Progestogens and estrogens, fixed combinations |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: DE | Bundesinstitut für Arzneimittel und Medizinprodukte | Identifier(s): 04653704, 04653710, 14357734, 15250263, 17582590, 17582609 |
Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 095906 |
Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100179310 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.